
A safe Dubai purchase starts with the exact strength, formulation, regimen, and regulatory status—not just the medicine name. You will be able to compare bicalutamide strengths, verify raltegravir 400 mg tablets, screen the packs and documentation, and identify the UAE import steps that must be completed before release.
Key takeaways
- Match bicalutamide 50 mg to the oncologist’s prescribed prostate cancer regimen.
- Review liver risk and interactions before approving bicalutamide or alternatives.
- Confirm raltegravir 400 mg tablets fit the patient’s complete HIV-1 regimen.
- Ask for batch details, expiry dates, packaging evidence, and import licence documents.
Choose the Bicalutamide Strength That Matches the Prescribed Regimen
The prescribed prostate cancer regimen—not the molecule name alone—determines which strength to source. Bicalutamide 50 mg is normally taken once daily with an LHRH agonist for metastatic prostate cancer. An LHRH antagonist may form part of the plan only when the oncologist specifies it.
| Strength | Treatment role | Sourcing decision |
|---|---|---|
| Bicalutamide 50 mg | Usually combined with an LHRH agonist; the hormonal component may need to start and continue at defined times | Confirm the LHRH medicine, dose schedule, start date, and continuation plan before release |
| Bicalutamide 150 mg | A separate high-strength regimen; do not assume it is suitable as monotherapy or alongside another treatment | Source only when the specialist prescription and local product information expressly support 150 mg |
Bicalutamide 150 mg is not simply three 50 mg tablets, and it is not interchangeable with the 50 mg-plus-LHRH regimen. The US CASODEX label does not approve 150 mg daily for use alone or with other treatments, so a buyer must not infer an indication from the strength.
- Request the exact strength, daily dose, and intended duration on the prescription.
- Do not split tablets to create a different dose unless a pharmacist confirms that the specific product is scored and suitable for splitting.
- If the prescription is unclear about the LHRH agonist or antagonist, pause supply and obtain clarification from the treating oncology team.
Screen Bicalutamide for Liver Risk, Interactions, and Non-Interchangeable Alternatives
Do not release bicalutamide until the prescriber’s regimen, liver status, and interacting medicines have been checked. Confirm whether the request is for 50 mg with an LHRH agonist or antagonist, or for 150 mg under a specifically documented oncology plan.
These strengths are not interchangeable, and bicalutamide 150 mg must not be treated as a routine substitute for 50 mg plus LHRH therapy.
- Obtain a baseline bicalutamide liver-function test and arrange regular monitoring, with particular attention during the first six months. Stop supply pending clinical review if jaundice, dark urine, severe fatigue, abdominal pain, or clinically significant enzyme elevation develops.
- Flag a warfarin interaction before dispatch. Bicalutamide can increase coumarin anticoagulant effects and prolong prothrombin time, so the treating team must set INR checks after initiation and dose changes.
- Confirm that the buyer has not requested bicalutamide as a replacement for abiraterone. The oncologist must select the medicine, not the product label alone.
- Check the intended LHRH component and its timing when 50 mg is requested; bicalutamide is not a general-purpose replacement for androgen-deprivation treatment.
| Bicalutamide versus abiraterone | Bicalutamide | Abiraterone |
|---|---|---|
| Mechanism | Blocks androgen-receptor signalling | Inhibits androgen production through CYP17 |
| Regimen | 50 mg commonly accompanies an LHRH agonist or antagonist | Usually accompanies ongoing androgen-deprivation therapy and a corticosteroid such as prednisone |
| Monitoring burden | Liver enzymes, symptoms, and anticoagulant effects | Liver enzymes, potassium, blood pressure, fluid retention, and corticosteroid requirements |
| Supply decision | Match strength and prescribed combination | Do not substitute without a revised oncology order |
Verify the Raltegravir 400 mg Formulation and Complete HIV-1 Regimen
Confirm the exact presentation before approving supply. Raltegravir 400 mg tablets are taken as one tablet twice daily as part of a complete HIV-1 combination regimen. They are not interchangeable tablet-for-tablet with the 600 mg once-daily raltegravir formulation.
| Presentation | Standard schedule or use | Procurement consequence |
|---|---|---|
| Raltegravir 400 mg tablets | One tablet twice daily | Confirm the prescription specifies raltegravir twice daily |
| 600 mg once-daily raltegravir | One 600 mg tablet once daily | Do not substitute for 400 mg tablets without clinical authorisation |
| Chewable tablets and oral suspension | Formulation-specific, often weight- or age-based dosing | Confirm the patient and prescribed dose before supplying |
A request for raltegravir alone is incomplete and clinically inappropriate. Ask for the companion antiretroviral regimen, treatment history, and prescriber confirmation; monotherapy increases the risk of virologic failure and resistance.
Resolve interactions before releasing the order:
- Check for rifampin. With raltegravir 400 mg twice daily, prescribing information specifies 800 mg twice daily when rifampin is used; do not make that dose change without the treating clinician’s instruction.
- Ask about aluminium- or magnesium-containing antacids, which can reduce raltegravir exposure and require product-specific clinical review.
- Confirm the patient is receiving the intended combination regimen, rather than treating the requested tablet strength as a complete treatment.
- Match the pack strength, dosage form, tablet count, and directions to the prescription; do not replace tablets with chewable tablets or oral suspension by assumption.
Inspect Every Medicine Pack Before You Approve the Purchase
Before approving a quotation or shipment, match the exact product to the requested medicine: bicalutamide 50 mg or 150 mg tablets, or raltegravir 400 mg tablets. A quotation that says only “bicalutamide” or “raltegravir” leaves strength, dosage form, manufacturer, and regulatory status unresolved.
- Ask for the approved manufacturer, manufacturing site, UAE registration status, and the licensed UAE importer. An Indian manufacturing licence, WHO-GMP evidence, or certificate of pharmaceutical product does not by itself authorize sale in Dubai.
- Check the carton and blister for the batch number and expiry date, matching them against the invoice, packing list, and certificate of analysis.
- Confirm approved local labeling: readable product name, strength, dosage form, storage instructions, batch details, expiry, manufacturer, and required Arabic or English information.
- Inspect tamper evidence. Reject packs with broken seals, crushed cartons, missing blisters, altered print, or labels placed over original details.
- Request shipment records showing continuous protection from excessive heat and humidity. These tablets generally need controlled room temperature, not refrigerated transport.
| Product | Pack identity to confirm | Traceability evidence |
|---|---|---|
| Bicalutamide | 50 mg or 150 mg tablet; exact manufacturer and site | Batch-specific certificate of analysis and matching pack details |
| Raltegravir | 400 mg tablet, not another raltegravir presentation | Batch-specific certificate of analysis and UAE-authorized labeling |
| Both | Intact carton, blister, seal, and storage statement | Invoice, packing list, shipping record, and importer documentation |
Complete the India-to-Dubai Pharmaceutical Import Checks
An India-to-Dubai shipment needs product authorization, an approved supply chain, and customs-ready records. Confirm UAE product registration for the exact bicalutamide strength or raltegravir 400 mg tablet, approved manufacturer and site, dosage form, and pack size before accepting a quotation. A generic listing of the active ingredient is not enough.
Before payment, obtain and match these documents:
- EDE pharmaceutical authorization or the applicable Emirates Drug Establishment approval for the product and import
- Evidence that the licensed importer in Dubai is authorised to handle medicines and will submit the customs declaration
- The Indian manufacturing licence, WHO-GMP evidence, and certificate of pharmaceutical product
- A current certificate of analysis showing the batch number, test results, manufacture date, and expiry date
- Commercial invoice, packing list, airway bill, and documents identifying the exporting manufacturer and consignee
Indian WHO-GMP status or a certificate of pharmaceutical product does not itself permit UAE sale. Product registration, manufacturer approval, importer licensing, and shipment release are separate checks.
Keep the cartons sealed, dry, and protected from Dubai heat and humidity. Standard tablets do not normally need refrigeration; follow the labelled storage range, commonly 20–25°C, and record temperature exposure during transit. Reject unexplained delays, damaged seals, mismatched batch numbers, or missing traceability records.
Cordium Pharmaceuticals Pvt Ltd should identify the registered product, approved site, Dubai importer, and shipment documents rather than provide only a brand name.
Related products
![]() | Oncology Medicine Tabi Tablets 50mg & 150mg in Dubai, UAE – Bicalutamide Tablets Tabi Tablets contain bicalutamide, an anti-androgen medicine used under medical supervision in the management of prostate cancer. |
![]() | Anti HIV Medicines Zepdon (Raltegravir) Tablets in UAE – Uses, Benefits, Dosage & Export Supply Zepdon (Raltegravir) Tablets contain raltegravir, an antiretroviral medicine belonging to the integrase strand transfer inhibitor (INSTI) class. |
Frequently asked questions
Which bicalutamide strength should you source?
The prescribed regimen determines the strength. Bicalutamide 50 mg is normally taken once daily with an LHRH agonist for metastatic prostate cancer; follow the oncologist’s prescription.
What safety checks matter before buying bicalutamide?
Screen for liver risk and medicine interactions, and do not treat bicalutamide as interchangeable with alternatives unless the prescriber confirms the change.
What should you verify about raltegravir 400 mg tablets?
Confirm the 400 mg tablet formulation and check that it is part of the patient’s complete HIV-1 treatment regimen.
What should you inspect on each medicine pack?
Check the product name, strength, dosage form, batch number, expiry date, seal, manufacturer details, and pack condition before approval.
Which documents matter for importing these medicines from India to Dubai?
Request the required product and shipment records, including the supplier’s licence details, invoice, packing list, batch documents, and Dubai import authorisations before dispatch.
Related products
![]() | Anti HIV Medicines RALMAC-400 Tablets – Raltegravir 400 mg for HIV Treatment RALMAC-400 Tablets contain raltegravir 400 mg, an antiretroviral medicine used in combination with other HIV medicines to manage HIV-1 infection. |
![]() | Oncology Medicine Abiraquick 250mg Tablets – Abiraterone Acetate Abiraquick 250mg Tablets contain abiraterone acetate 250 mg, an anti-cancer medicine used in the management of certain forms of advanced prostate... View product → |










